Support teaching, research, and patient care.
Dr. Seth L. Sherman is a third-generation team physician and surgeon. He is board certified and fellowship trained in Sports Medicine. Dr. Sherman is proud to serve as Orthopedic Surgeon for Stanford Cardinal Football and as the Sports Medicine fellowship director. Dr. Sherman specializes in arthroscopic and minimally invasive surgical interventions for the knee and shoulder. He has subspecialty and research interests in knee joint preservation/cartilage restoration and the patellofemoral joint. As a tertiary care provider, Dr. Sherman offers non-surgical and salvage surgical solutions for active patients with complex problems and in cases where other surgeries have failed. Dr. Sherman completed his residency training at the Hospital for Special Surgery in New York City and was trained by the team physicians for the NY Giants, Mets, and Knicks. During his sports medicine fellowship in Chicago , he served as assistant team physician for the Chicago Bulls and White Sox. Prior to joining the team at Stanford University in July 2019, he served as team physician for the Mizzou Tigers in the NCAA SEC conference. Dr. Sherman is co-author on more than 100 peer reviewed articles/chapters and actively presents his research at national and international meetings. He is Chairman of the AAOS Sports Medicine/Arthroscopy committee and holds leadership positions in several other organizations (AOSSM, AANA, ISAKOS, ICRS). He is a member of the prestigious international ACL and Patellofemoral Study Groups.He enjoys spending time with wife Sylvia and daughter Evie. He is an avid fresh and saltwater fly fisherman.
My research focuses on ways to augment tissue healing, improve human performance, and prevent musculoskeletal injuries. Approaching these challenges through parallel basic science and clinical pathways, our team works from the “bedside to the bench and back to the bedside”, identifying areas of clinical need to deliver evidence-based solutions for patients. We collaborates with orthopaedic surgeons, non-surgical physicians, and researchers within bioengineering, human performance, and musculoskeletal imaging across the Stanford campus. The team is developing novel methods to accurately record human movement (including wearable technology, phone-based systems), rapid MRI imaging protocols, and exploring the use of biomarkers to track injury and recovery. This research builds on my earlier work, which utilized portable, inexpensive software for Microsoft Kinect to detect knee injury risk in youth athletes performing a drop vertical jump test. The team’s multifaceted goal is: 1) develop innovative methods to screen for injury risk (i.e. youth athlete non-contact ACL), 2) create targeted intervention programs to reduce risk, 3) enhance athletic performance; and 4) improve accuracy of return to play testing following injury/surgery (i.e. clinical evaluation, biomarkers, functional tests, imaging analysis for healing).In the laboratory,our team investigates cellular and molecular deficiencies in tissue types including tendon, ligament, articular cartilage, and meniscus. By understanding aberrant pathways leading to tissue injury, they can identify innovative therapeutic targets for intervention. In collaboration with the Genetic Engineering and Synthetic Biology laboratories, Dr. Sherman’s research has explored the role of orthobiologic agents such as platelet rich plasma (PRP) and bone marrow aspirate concentrate (BMAC) for tissue healing in patella tendinopathy (the breakdown of collagen in a tendon). Our lab is also investigating the use of CBD for musculoskeletal applications as an alternative to commonly used local anesthetics and cortisone derivatives. In my earlier work, we researched the cellular toxicity of such applications. In addition to basic science research, I have helped to build a Sports Medicine clinical research team that includes several full-time clinical research coordinators, residents, fellows, and students. The team collects prospective outcomes on their patients using a novel data collection platform called Patient IQ. The group is part of the JUPITER study which is the largest, multicenter study ever assembled in patellofemoral instability. They are additionally planning to enroll in FDA-approved clinical studies investigating pioneering strategies for knee cartilage restoration, joint preservation, and orthobiologic injections for osteoarthritis. Recent clinical publications explore outcomes in meniscus preservation and transplantation, medial patellofemoral ligament reconstruction, osteochondral allograft and matrix-induced autologous chondrocyte implantation (MACI), and surgical augmentation using PRP/BMAC. The clinical research team actively reports results of non-surgical and surgical interventions to continue to introduce new knowledge to the field, with the goal of improved patient outcome.
The Effect of Micro Fragmented Adipose Tissue (MFAT) on Knee Osteoarthritis
This is a non-surgical trial comparing the clinical and functional outcomes of patients with
osteoarthritis treated with Intra-articular injection of Micro Fragmented Adipose Tissue
versus conventional therapy of intra-articular injection of corticosteroid.
View full details
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
The purpose of this study is to compare the clinical and functional outcomes of patients with
mild to moderate arthroscopically confirmed osteoarthritis between the following two groups:
1. Partial fat pad harvest with Adipose-Derived Stem Cell (ADSC) transplantation with
standard arthroscopic treatment consisting of: partial meniscectomy, cartilage
stabilization, loose body removal and selective synovectomy.
2. Standard arthroscopic treatment (above) with out cell transplant.
Subchondroplasty® Knee RCT
This is a multi-center, prospective, single-blinded, two-arm study, randomized to include
approximately 134 subjects treated with Subchondroplasty (SCP) + Arthroscopy and 67 subjects
with arthroscopy alone.
The primary objective of this study is to demonstrate superiority of Subchondroplasty with
arthroscopy compared to arthroscopy alone for treatment of Bone Marrow Lesions (BMLs) in the
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
The purpose of this study is to compare two biologic methods for the treatment of articular
cartilage defects in the knee. The first method, microfracture, is the standard of care and
is routinely used to recruit cells from the subchondral bone marrow to the site of cartilage
loss. The second method is the application of adipose-derived stem cells (ADSCs) to the
defect site. In theory, ADSCs on a collagen scaffold should enable the delivery of more
specific progenitor cells to the site of injury, resulting in better regeneration and
integration of articular cartilage at the site of a defect as compared to the microfracture